Combination Product Development
Product Description
Coriolis
-
Country/Region:Germany
-
On CPHI since:2022
-
Certificates:1
-
Employees:100 - 249
Company types
Primary activities
Categories
Coriolis
-
Country/Region:Germany
-
On CPHI since:2022
-
Certificates:1
-
Employees:100 - 249
Company types
Primary activities
More Products from Coriolis (8)
-
Product Manufacturing Services
We support our clients with the production of non-GMP drug product batches for preclinical and indicative stability studies, including
• Liquid drug product manufacturing • Lyophilized drug product manufacturing • Analytics and stability testing -
Product Formulation Development
We develop phase-appropriate formulations for liquid, frozen and lyophilized drug products, focusing on your target product profile (TPP) and designing the study to meet your requirements.
Our offering includes:
- Preformulation Screening
- Preclinical Formulation Development
-... -
Product Lyophilization Process Develpment and Lyo Modelling
Coriolis Pharma’s team of experts specializes in lyophilization, bringing extensive experience in developing, optimizing, scaling up, and transferring lyophilization cycles for biopharmaceutical drug products. Our advanced approaches are designed to create robust, economical freeze-drying cycles by impleme... -
Product Stability Studies (Non-GMP and GMP)
As part of formulation development projects, supply of preclinical, clinical or commercial material, or as a standalone service package, Coriolis performs stability studies in accordance with ICH guidelines using suitable climate chambers at controlled temperatures and relative humidity (RH). In addition t... -
Product Release Testing
Coriolis Pharma offers release testing services to ensure that drug products meet their intended target product profile, safety, efficacy, and regulatory standards. Our analytical offerings include both compendial and custom methods for purity, identity, potency, particle and aggregate analysis, polysorbat... -
Product Particle Identification
Observing visible and subvisible particles can stagnate the drug development or the batch release process. Coriolis Pharma has the experience and the capacity to determine the identity and possible origin of particulate matter in your biopharmaceutical drug products—crucial for troubleshooting and root-cau... -
Product Phase-Appropriate Drug Product Development Services
We support our clients from early-stage research and preclinical phase to and beyond market approval by providing comprehensive development services, including
• Developability assessment • Pre-formulation screening • Formulation development • Lyophilization process development • Forced d... -
Product Analytical Services (GMP and R&D)
Our analytical portfolio comprises 200+ different techniques – all performed by Coriolis’ experts in-house. Our offering includes:
• Aggregate analytics • Particle characterization • Particle identification • Surfactant characterization • Higher order structure analysis • Funcional assays • Chemi...
Coriolis resources (15)
-
News Article: In Silico and Laboratory Developability Assessment
This new article from Coriolis Pharma highlights how early developability assessments can prevent late-stage failures. By integrating lab-based and in-silico analyses, Coriolis identifies risks early, optimizes formulations, and supports faster, more cost-effective drug development from discovery to market.
-
Industry Webinar Lyo-Modelling – Reduce risks on the road to commercialization through process understanding
This webinar presents a comprehensive overview of a lyophilization model including a robustness analysis, highlighting the significance of predictive models and robustness assessment methodologies in optimizing process parameters and ensuring product quality. -
News Article: Biologic Stability with Lyophilization
This new article from Coriolis Pharma explores how lyophilization supports the stability and scalability of biologics. By combining quality-by-design, predictive modeling, and advanced freeze-drying technologies, Coriolis ensures robust, manufacturable formulations ready for global deployment.
-
Industry Webinar Smarter Drug Development for Biologics with In-Silico Modelling
The on-demand webinar includes case studies demonstrating in silico modeling’s role in developability assessment and early formulation development, highlighting how these approaches minimise risks, shorten development times, and enhance decision-making. -
News Article: Advancing Subvisible Particle Characterization with AI
This new article from Coriolis Pharma presents AI-powered flow imaging microscopy as a breakthrough in particle analysis. Through its partnership with ParticleSentryAI, Coriolis enables deeper particle insights, supporting better formulation decisions, improved product quality, and faster development of safe biopharmaceuticals. -
Brochure Company Overview
Learn more about Coriolis Pharma, your partner for drug product development, analytical and manufacturing services. -
News Article: Leveraging GMP Release and Stability Testing Methods
This new article from Coriolis Pharma underscores the critical role of GMP-compliant analytical testing in ensuring drug quality and stability. It highlights the need for specialized methods to manage complexity, support regulatory compliance, and safeguard product integrity throughout development. -
Brochure Lyophilization Process Development and Lyo Modeling
Coriolis Pharma’s team of experts specializes in lyophilization, bringing extensive experience in developing, optimizing, scaling up, and transferring lyophilization cycles for biopharmaceutical drug products. -
News Article: The Importance of a Robust Formulation
This new article from Coriolis Pharma emphasizes the importance of robust formulations for biologic drug success. It showcases Coriolis’ integrated, science-driven approach using in-silico tools and high-throughput methods to create stable, future-ready formulations from early development onward. -
Brochure Developability Assessment
Our developability assessment service combines laboratory-based and in silico developability assessments to provide early insights into molecule characteristics and potential liabilities, optimize formulations, and mitigate risks. -
News Article: From Prefilled Syringes to On-body Devices
This new article from Coriolis Pharma highlights the growing need for high-concentration biologic formulations suited for self-administration. It outlines Coriolis’ expertise in overcoming formulation and packaging challenges to deliver stable, user-friendly therapies ready for clinical and commercial success.
-
Industry Webinar Every Particle Matters: Identify Visible and Subvisible Particles in Your Biologic and Gene and Cell Therapy Drug Product
In this webinar our experts talk about tools and methods for particle identification and characterization in biologics and gene and cell therapy drug products.
